Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T cells for CD19+ B-cell hematologic malignancies
ChiCTR-OIC-16008291Phase 2Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Apr 2016
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CD19 CAR-T cells in B-cell hematologic malignancies, B cell acute lymphoblastic leukemia (B-ALL) and malignant B-cell neoplasm, sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Complete remission rate. Started Apr 2016; status: recruiting.
02
Drugs
CD19 CAR-T cells
03
Conditions
B-cell hematologic malignanciesB cell acute lymphoblastic leukemia (B-ALL)malignant B-cell neoplasm
Beyond the preview
Go deeper on ChiCTR-OIC-16008291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OIC-16008291.